Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis

Sirolimus (rapamycin) has been sparsely reported in the treatment of pediatric ulcerative colitis (PUC). Mucosal healing has not been examined in responders to the drug. We describe a case of infliximab refractory PUC where rapamycin induced sustained clinical remission along with mucosal healing. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Kellermayer, Richard, Chang, Andrew, Patel, Kalyani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins, Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158451/
https://www.ncbi.nlm.nih.gov/pubmed/37168909
http://dx.doi.org/10.1097/PG9.0000000000000183
_version_ 1785036932502257664
author Kellermayer, Richard
Chang, Andrew
Patel, Kalyani
author_facet Kellermayer, Richard
Chang, Andrew
Patel, Kalyani
author_sort Kellermayer, Richard
collection PubMed
description Sirolimus (rapamycin) has been sparsely reported in the treatment of pediatric ulcerative colitis (PUC). Mucosal healing has not been examined in responders to the drug. We describe a case of infliximab refractory PUC where rapamycin induced sustained clinical remission along with mucosal healing. We conclude that rapamycin should be positioned into the expanding treatment repertoire of PUC.
format Online
Article
Text
id pubmed-10158451
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins, Inc.
record_format MEDLINE/PubMed
spelling pubmed-101584512023-05-09 Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis Kellermayer, Richard Chang, Andrew Patel, Kalyani JPGN Rep Case Report Sirolimus (rapamycin) has been sparsely reported in the treatment of pediatric ulcerative colitis (PUC). Mucosal healing has not been examined in responders to the drug. We describe a case of infliximab refractory PUC where rapamycin induced sustained clinical remission along with mucosal healing. We conclude that rapamycin should be positioned into the expanding treatment repertoire of PUC. Lippincott Williams & Wilkins, Inc. 2022-03-17 /pmc/articles/PMC10158451/ /pubmed/37168909 http://dx.doi.org/10.1097/PG9.0000000000000183 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kellermayer, Richard
Chang, Andrew
Patel, Kalyani
Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis
title Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis
title_full Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis
title_fullStr Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis
title_full_unstemmed Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis
title_short Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis
title_sort sirolimus (rapamycin) induced mucosal healing in anti-tumor necrosis factor refractory pediatric ulcerative colitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158451/
https://www.ncbi.nlm.nih.gov/pubmed/37168909
http://dx.doi.org/10.1097/PG9.0000000000000183
work_keys_str_mv AT kellermayerrichard sirolimusrapamycininducedmucosalhealinginantitumornecrosisfactorrefractorypediatriculcerativecolitis
AT changandrew sirolimusrapamycininducedmucosalhealinginantitumornecrosisfactorrefractorypediatriculcerativecolitis
AT patelkalyani sirolimusrapamycininducedmucosalhealinginantitumornecrosisfactorrefractorypediatriculcerativecolitis

Ejemplares similares